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Abstract 
 
Introduction: Renal tract malformations (RTM) are congenital anomalies of the kidneys and 
urinary tract, which are the major cause of end stage renal disease in children. Using 
immunoassay-based approaches (ELISA, western blot), individual urinary proteins including 
transforming growth factor β, tumor necrosis factor and monocyte attractant proteins 1 were 
found to be associated to RTM. However, only mass spectrometry (MS) based methods 
leading to the identification of panels of protein-based markers composed of fragments of the 
extracellular matrix allowed the prediction of progression of RTM and its complications. 
Areas covered: In this review, we summarized relevant studies identified in “Pubmed” using 
the keywords “urinary biomarkers” and “proteomics” and “renal tract malformations” or 
“hydronephrosis” or “ureteropelvic junction obstruction” “posterior urethral valves or 
“vesicoureteral reflux”. These publications represent studies on potential protein-based 
biomarkers, either individually or combined in panels, of RTM in human and animal models. 
Expert commentary: Successful use in the clinic of these protein-based biomarkers will 
need to involve larger scale studies to reach sufficient power. Improved performance will 
potentially come from combining immunoassay- and MS-based markers.  
 
Keywords: proteomics; children; urine; biomarkers; renal tract malformation 
1. Introduction 
Renal tract malformations (RTM) are congenital anomalies of the kidneys and/or lower 
urinary tract. Severe RTM is life-threatening and only a limited number of RTM can be 
successfully (surgically) corrected, e.g. ureteropelvic junction obstruction (UPJO) and to a 
lesser extent posterior urethral valves (PUV). Severe, not surgically correctable, RTM will 
  
lead in many cases to end stage renal disease (ESRD) (1;2). Hence, key issues in the 
clinical management of RTM, which is often detected in utero, are the prediction of disease 
progression and management of its complications.  
Hippocrates linked health problems to diagnostic changes in the urine two millennia ago. 
Presently, measurement of urinary components such as proteins to test for the presence of 
kidney disease, using dipsticks and standard laboratory tests, is routine in diagnostics. 
However, these tests lack sensitivity and consequently detect kidney disease often at a late 
stage since there has to be significant kidney damage before frank proteinuria occurs. 
Therefore, identification of earlier and prognostic markers using, for example proteomics 
techniques, would be desirable. Indeed the use of proteome analysis for the discovery of 
clinically relevant proteins, known as “clinical proteomics”, is perceived to be the most 
relevant discipline to foster the translation of basic discoveries into clinical applications for 
the benefit of the patient (3). Clinical proteomics needs to adhere to strict guidelines to 
generate clinically useful biomarkers of disease. Therefore, Mischak et al. asserted that 
successful clinical proteome studies should in general use stringent statistical approaches for 
biomarker definition and that results should always be confirmed in independent test sets (4). 
In addition, they described a brief set of practical and feasible recommendations for 
investigators to properly identify and qualify proteomic (or any other) biomarkers, which could 
also be used as reporting requirements. Such recommendations should help put proteomic 
biomarker discovery on solid ground.  
 
2. Urine as a source of biomarkers of RTM  
Easily accessible biological samples, such as plasma, serum or urine are valuable sources of 
biomarkers. Particularly urine which can be collected in large quantities and in non-invasive 
fashion and is less complex than for example plasma (5;6). Under physiological conditions, 
70% of urinary proteins are produced by kidney and urinary tract and hence urine is a 
potential source of biomarkers for RTM. However, urine also allows to obtain information 
related to various other organs because of the glomerular filtration of blood (7). The urinary 
  
proteome is relatively stable, because it is stored for hours in the bladder at 37°C and any 
proteolysis has been completed at time of voiding (8). Therefore, the urinary proteome does 
not change significantly and urine can be stored for 6 h at room temperature or 3 days at 4ºC 
as well as for several years at -20°C (9). In addition to full length proteins, urine also contains 
many naturally occurring low molecular weight proteins (peptides), which can be directly 
analysed by mass spectrometry, without additional sample processing, such as tryptic 
digestion and the depletion of abundant blood-derived proteins (10;11). Variability in the 
protein/peptides concentration is the main disadvantage of urine. These variations are 
caused by the differences of the protein quantity during the day, circadian rhythms, exercise, 
diet and metabolic or catabolic processes (10;12). However, this can be corrected by using 
normalization methods (13).  
 
3. Proteome analysis-based approaches for the identification and validation of 
biomarkers 
The main goal of clinical proteomics is the identification of biomarkers, providing information 
to improve and personalize medicine (14). Since, by definition, the proteome is complex, its 
analysis needs in general two steps: firstly, fractionation of the proteins into smaller less 
complex subsets followed by, secondly, analysis of the protein abundance and protein 
identity by mass spectrometry (MS) of those fractions. Fractionation is/has been often 
performed by chromatographic techniques including two-dimensional gel electrophoresis (2-
DE), liquid chromatography (LC) and capillary electrophoresis (CE). The protein fractions are 
then analysed off- or on-line by MS. 2-DE, cumbersome and low-throughput, has now mostly 
been abandoned. The advantages and disadvantages of these proteomics techniques have 
been extensively described in several reviews (10;15;16) and will not be discussed here.  
Enzyme-linked immunosorbent assays (ELISA) are frequently cited for validation and clinical 
application of protein-based markers of disease. However, antibodies have the limitation that 
they only recognize a particular epitope and therefore one antibody cannot differentiate 
between isoforms (17;18) or highly similar peptides (19-21) that are often disease specific. 
  
Another drawback of the use of antibodies is antibody cross-reactivity and protein/protein 
interactions that may modify the quantification of the results (22;23). Furthermore, although 
ELISAs supports multiplexing this is limited to a maximum number of proteins which often 
does not cover the several 10-100 of proteins of which biomarker panels are currently 
composed of (24-26). Finally, although MS-based techniques need an initial large investment 
for the MS-equipment, ELISAs are relatively expensive in use and in the long run will cost 
more than MS-based techniques (27;28).  
Selected reaction monitoring (SRM) and multiple reaction monitoring (MRM) are 
selective/targeted MS-based techniques for protein quantification and identification of small 
proteins/peptides. High specificity, sensitivity, fast analysis, and the quantification of targeted 
proteins/peptides are some advantages of these proteome analysis based methods that can 
be employed in biomarker discovery, verification and validation (29-31). These techniques 
might become the references for clinical analysis of sets of proteome-based markers 
although large scale studies proving the feasibility still need to be undertaken. To our 
knowledge MRM has not yet been used in the context of RTMs. Finally, in recent years 
several studies have also demonstrated the importance of CE-MS in validation of 
biomarkers, due to low cost and high-throughput, as well as high reproducibility, allowing this 
proteomic approach to be essential for clinical application. 
 
 
 
4. Renal tract malformations 
RTM are considered as the primary cause of chronic renal failure in children (30-50%). RTM 
can be unilateral or bilateral involving the upper or low urinary tract or only the kidney and 
combinations thereof, as depicted in figure 1 (30;31). For example ureteropelvic junction 
obstruction (UPJO) is often unilateral and represents an obstruction at the intersection of the 
kidney pelvis and the ureter, blocking normal urine flow and inducing in severe cases a 
hydronephrotic kidney (32). Posterior urethral valves (PUV) normally disappear during 
  
development, but in PUV remain and block urine outflow from the bladder leading to bilateral 
obstruction of urinary pathways with associated (often severe) lesions in the kidney (33;34). 
Vesicoureteral reflux (VUR) is characterized by a backward flow of the urine from the bladder 
towards the kidneys often due to urinary tract infection or urinary tract abnormalities. Severe 
VUR can lead to renal scarring, arterial hypertension and impaired renal function (35). RTM 
display a wide spectrum of pre- and postnatal outcomes ranging from death in utero to 
normal postnatal function. Most of the diagnostic methods of RTM are based on pre- and 
post-natal imaging, either ultrasound or radiological tests. However, imaging even if in some 
cases combined with fetal urine/amniotic fluid biochemistry, does often not help to provide 
the prediction of RTM progression and or its complications (31). Hence a number of studies 
have looked at the value of proteome analysis in RTM. Table 1 summarizes potential human 
urinary proteome analysis-based biomarkers of RTM that will be described in detail in the 
next sections. 
 
4.1. UPJO 
UPJO is the most common cause of upper tract obstruction and can be detected by 
ultrasound before birth (20;32). Currently UPJO is treated surgically in the easily detectable 
severe cases. However for the other patients with mild forms of obstruction close follow-up 
during the first years of life is required which is necessitating imaging and frequent hospital 
visits to determine the progression of the disease. ELISA and MS-based urinary proteome 
studies have been performed with the aim to identify urinary biomarkers of UPJO. Several 
groups used sandwich ELISA kits to discover and identify potential biomarkers of UPJO 
based on predefined knowledge obtained in animal models of obstruction or processes 
repeatedly observed in kidney disease progression (e.g. fibrosis, inflammation).  
Taha et al. were the first to study urinary concentrations of transforming growth factor β1 
(TGF-β1) in UPJO. Using a quantitative sandwich ELISA kit and a cohort of 35 children with 
UPJO and 30 healthy children, they observed that the expression of TGF-β1 was significantly 
increased in urine of children with UPJO (36). Interestingly, urinary TGF-β1 decreased after 
  
pyeloplasty (corrective surgery to remove the UPJO). These results were confirmed by 
Gawłowska-Marciniak et al., who used ELISA for their investigation of urine from the bladder 
and renal pelvis of 45 patients undergoing pyeloplasty and 25 controls (37) and by Sager et 
al. who used bladder urine from 19 UPJO patients and 19 matched controls (38). In another, 
more recent study, based on a cohort of 25 healthy controls and 25 children with UPJO, the 
authors also detected increased TGF- β1 levels in urine of patients with UPJO and a 
significant correlation of TGF-β1 with hydronephrosis grade (p=0.0001) (39).  
Studies of association between urinary EGF concentrations and UPJO were less successful 
because several studies described contradictory results. In 2000, ELISA was used in a study 
examining 24 patients with UPJO and 15 healthy children. Grandaliano et al. (40) established 
that EGF levels were significantly lower in UPJO patients when compared with healthy 
controls. These results, employing ELISA, were confirmed by Bartoli et al. (41) using a cohort 
of 76 UPJO patients and 30 healthy children. Li et al. (42) analyzed the urinary EGF values 
in 33 healthy subjects and 12 patients with UPJO (surgical group) and they also observed, 
using ELISA, a significant decrease in abundance in patients group, during the first six 
months of life. The data presented also supported the hypothesis that urinary EGF changes 
over time are inversely correlated with Society of Fetal Urology (SFU) hydronephrosis grade. 
However, Taha et al. did not find significant differences in urinary EGF concentrations 
between controls and surgical groups as well as preoperative and postoperative values one 
year after surgery (36). Furthermore, using a cohort of 28 UPJO children and 13 controls and 
a bead-based multiplex sandwich immunoassay, EGF levels according to Madsen et al. (43) 
were significantly increased in UPJO patients (submitted to pyeloplasty) compared to 
controls. Furthermore, a 3 months and 1 year follow-up showed that these values normalized 
with similar values between patients and controls. Based on these contradictory results, it 
seems that EGF is not a valid biomarker for UPJO, because EGF levels were decreased in 
some studies (40-42), increased in another (43) or without changes (36).  
The same studies also investigated specific urinary cytokines, such as monocyte 
chemotactic peptide 1 (MCP-1) for its use as a biomarker for UPJO (40;41;43). Comparing 
  
patients subjected to pyelopasty (preoperative and postoperative) and healthy controls, 
Grandaliano et al. (40) demonstrated that preoperative values of MCP-1were significantly 
increased. These findings were verified by Bartoli et al. (41) and Madsen et al. (43). They 
reported increased concentrations of this cytokine in urine of preoperative UPJO patients and 
a decrease in postoperative UPJO patients (similar to healthy). 
Several, more anecdotal, studies focusing on the association of urinary angiotensinogen 
(AGT), kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin 
(NGAL) to UPJO were recently published: Taranta-Janusz et al. compared 31 children with 
severe hydronephrosis (who needed surgery); a non-surgical group, 20 patients with mild 
hydronephrosis, and 19 healthy children to study the urinary AGT concentration with the use 
of a commercially available ELISA (44). They observed that increased levels of AGT were 
directly correlated with UPJO children. AGT was also found in a later study (45), but the 
researchers turned no special attention to this protein. 
A study involving 20 children with severe hydronephrosis, two groups of healthy individuals, 
20 patients with mild non-obstructive hydronephrosis and 25 healthy children, demonstrated 
using immunoenzymatic ELISA commercial kits an increase in urinary NGAL and KIM-1 and 
established a correlation with worsening obstruction (46). The results for NGAL were 
confirmed in another study, presenting an increase in urine from patients with obstructed 
kidneys at the time of surgery. This increase was followed by a decrease and stabilization to 
the same level as that of the controls (47).  
Although these individual proteins were associated, with different degrees of confidence, to 
the severity and grade of UPJO, none of the studies evaluated their predictive power which 
would be the main use of urinary markers in UPJO. 
 
MS-based proteomics approaches have been performed to predict the progression of UPJO, 
and the results were validated in several studies. The urinary proteome of 13 healthy 
newborns, 19 UPJO patients with mild obstruction (non-operated individuals (no-OP)) and 19 
UPJO patients with severe obstruction (operated individuals (OP)) was analysed using CE-
  
MS by Decramer et al. (51). They established a classifier based on 51 UPJO-specific urinary 
peptide biomarkers to differentiate resolution of UPJO or the requirement of pyeloplasty. 
Validation of these 51 biomarkers combined in a support vector machine (SVM) panel in an 
independent group of OP and no-OP patients (n=16) resulted in 94% sensitivity and 80% 
specificity. In a blinded cohort of 36 UPJO patients with 9 months of follow-up this panel 
predicted with 95% accuracy whether an infant with UPJO needed surgery. This biomarker 
panel was further validated in 19 children where the classifier displayed 83% sensitivity and 
92% specificity. However in UPJO patients >1 year of age, this classifier lost sensitivity 
(66%) and specificity (20%) (52). This is probably due to the change of the urinary proteome 
after the age of 1-2 years (53). It also points to the fact that the context of use of disease 
classifiers will often not be beyond the population in which it was defined.  
Bandin et al. used CE-MS-based urinary proteome analysis to determine whether early 
surgically corrected UPJO would normalize the urinary proteome after long-term follow-up 
compared to conservatively followed UPJO patients (54). Studying 42 patients with UPJO 5 
year after either pyelopasty or spontaneous resolution of the obstruction, they observed that 
the urinary proteome was very similar in patients with early surgical correction of UPJO and 
age matched controls. However the urinary proteomes of UPJO patients leading to 
spontaneous resolution or late surgical intervention did not normalize and displayed a 
significantly different pattern (54). This suggests ongoing renal or ureteral remodeling in the 
conservatively followed patients that is not visible clinically. 
LC-MS/MS coupled to bioinformatics analysis was used in a number of studies to evaluate 
the urinary proteome of infants with UPJO. According to these studies, the most prominent 
proteins found were related to pathways involving inflammation, oxidative stress, fibrosis and 
renal disease (48;55-57). Mesrobian et al. (56;57) have identified the proteome differences 
between normal infants and infants with UPJO. In the first study, using 21 healthy infants and 
25 infants with grade IV unilateral ureteropelvic junction obstruction, they identified 31 
proteins changing at different time-points (56). In the second study, differences in individual 
urine samples were assessed in 21 healthy infants and 25 infants with grade IV unilateral 
  
UPJO followed for 5 years. The urinary proteome from patients with UPJO was different from 
the age-matched controls, based on the activation of processes of inflammation, apoptosis, 
tubular injury and fibrosis, and oxidative stress (57). 
A proteomic study of urine samples (n=5/group) from newborns with UPJO at different stages 
and controls was performed. Urine protein profiles of these patients were obtained by label 
free quantitative nanoLC-MS/MS and 970 urinary proteins were identified (52). In a recent 
case-control study (8 controls and 8 subjects with unilateral obstruction), Froehlich et al. (45) 
reported correlation between identified and quantified proteins associated with this type of 
RTM. They identified 1113 proteins, but only 76 were significantly different between the two 
groups. In particular biological processes such as inflammation and renal disease pathways 
showed significant variations, targeted oxidative stress proteins were also presented over 
expressed. 
Based on these studies, potential regulated proteins in RTM such as arginase 1, glutathione 
S-transferase Mu 1 (GSTM1) and heat shock 70 kDa protein 1A (HSPA1A) were further 
studied and validated. Using Western Blot and MRM analysis, a decrease in arginase 1 in 
UPJO was validated in independent samples. In addition, in a mouse model of obstructive 
nephropathy, arginase 2 and total arginase activities were found to be increased (52). 
GSTM1 and HSPA1A were also validated by Western Blot and confirmed that these proteins 
were elevated in urine of UPJO patients, supporting the idea that alterations in the 
processing of reactive oxygen species (ROS) are related to UPJO.  
These urinary proteome analysis studies were also an opportunity to re-evaluate the unclear 
association of urinary EGF to UPJO obstruction observed using ELISA. However, again 
contradicting results were obtained. Lacroix et al. (52) observed that urinary EGF decreased 
in UPJO using a combination of targeted (MRM) and non-targeted MS/MS analyses (using 
an independent cohort, n=10/group), and also demonstrated that EGF was among the top 
differentially excreted proteins. In contrast, Froehlich et al. (45) did not report EGF among the 
differentially expressed urinary proteins in their study. Hence EGF appears, again, not to be 
a reliable marker of UPJO. This might be due to the fact that urinary EGF is also modified in 
  
other renal diseases including acute kidney injury, diabetic nephropathy, chronic kidney 
disease, IgA nephropathy, Lupus nephritis etc. (55) or even in different types of cancer (56), 
which demonstrates that EGF is not exclusively specific to UPJO.  
 
4.2. PUV 
Posterior urethral valves (PUV), the prototypic bilateral RTM (37), is an abnormal congenital 
obstructing membrane that is located within the posterior male urethra; this valve is the most 
common cause of bladder outlet obstruction in male children (36). The valve is believed to 
result from abnormal embryologic development of the fetal posterior urethra. The classic 
categorization of posterior urethral valves into types I, II, and III was developed by Young et 
al. in 1919 (60) and has undergone modification over time based on clinical observation and 
a better understanding of the embryologic events that lead to normal urethral development. 
This anomaly is not related with genetic disorders; however it was reported with familial 
inheritance (61). In PUV the major aim is the timing of surgical intervention (pre- or post-
natal) and the prediction of the progression stage of chronic kidney disease (CKD) (34).  
CE-MS has been applied in a cohort of 28 patients with PUV with the aim to identify fetal 
urinary biomarkers that allow prediction of post-natal renal function (62). In that study Klein et 
al. identified 26 specific fetal urinary peptides biomarkers that characterized early ESRD. 
Twelve of these 26 peptides were combined in a classifier called the “12PUV” classifier, 
which displayed a sensitivity of 86% and a specificity of 95% for the prediction of post-natal 
renal function in an independent validation cohort of 38 patients with PUV. The main markers 
associated to early ESRD in PUV were collagen fragments. One particularity of this study 
was the abundance of these collagens in disease. Collagens were increased in fetal urine of 
patients with PUV displaying early ESRD. This is the opposite to what is observed in 
postnatal urine in patients with CKD (62) suggesting that instead of fibrosis in CKD, patients 
with PUV display increased extracellular matrix turnover due to disruption of nephrogenesis 
(visible as dysplasia or hypoplasia in fetopathology). One fetal urinary biomarker of early 
ESRD was identified as a fragment of the XLαs variant of the G-protein-α subunit (GNAS). 
  
GNAS and its variants represent imprinted genes (specific maternally or paternally 
transmitted active copies of genes due to methylation patterns) and are described to have 
major effects on growth in utero and after birth.  
Trnka et al. studied the potential correlation between post-natal urinary protein levels and 
kidney function in patients with PUV (63). In total, 47 subjects were studied: 27 patients with 
PUV and 20 controls, performing immunoblotting technique as well as determination of 
glomerular filtration rate (GFR). They were able to demonstrate significant differences in the 
excretion of some proteins between the two groups. Aquaporin-2 was significantly 
decreased. On the other hand, the urinary protein-to-creatinine, whole-urine TGF-β and L1 
cell adhesion molecule (L1CAM) were considered the best potential biomarkers, because 
they were significantly increased in urine of PUV patients and presented better correlation 
with GFR.  
Using post-natal urine of 30 patients with PUV, Mandelia et al. investigated a number of 
urinary proteins and also the effects of angiotensin-converting enzyme inhibitors (ACE-I) on 
renal recovery (64). The pre- and postoperative protein levels of TGF-β1, tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL-6) and microalbuminuria were measured over a period of 1 
year. TGF-β1, TNF-α, and microalbuminuria were increased in patients with PUV. These 
proteins can be potential biomarkers because they reflect potential activation of the renin–
angiotensin system, as well as they can provide an early recognition of children with ongoing 
renal damage. The treatment with ACE-I indicated an improvement of the kidney physiology 
and decrease of urinary TGF-β1 and microalbuminuria, allowing the retarding of renal injury 
in PUV patients and preserve the renal function in PUV patients (64). 
 
4.3. VUR 
Vesicoureteral reflux (VUR) can be detected and diagnosed by voiding cystourethrography 
which is an invasive and uncomfortable method for the children (38). VUR is frequently 
genetically heterogeneous, and emerges from interruption of complex signaling pathways as 
well as cell differentiation, which may be influenced by environmental factors (65). Urine from 
  
73 children was collected and analyzed by CE-MS. To identify potential biomarkers, 18 
patients with primary VUR (grade IV or V) and 19 patients without VUR were used. Nine 
urinary peptides were found, which were differentially regulated and a VUR-classifier was 
generated based on these peptides. A subsequent blinded evaluation has been performed 
on 17 patients with VUR grade IV or V and 19 patients without VUR with 88% sensitivity and 
79% specificity. Five of the nine urinary biomarkers were successfully sequenced. They 
included 3 collagen alpha-1 (I) chain fragments, a sodium/ potassium-transporting ATPase 
and a CD99 antigen fragment. 
 
5. Urinary RTM biomarkers from animal models 
The UPJO animal model is the most frequently used RTM animal model. This model was 
used to study potential protein-based urinary markers of the disease including interleukin-1β 
(IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin 10 (IL-10)), TNF-α, and interferon-
γ (IFN-γ), etc. that are known to act as intercellular mediators in the cellular and molecular 
events of in UPJO.  
Madsen et al. performed a study using two different rat UPJO models (the basic rat model is 
depicted in figure 2) to analyze the urinary abundance of these different potential biomarkers 
with the use of a bead-based multiplex sandwich immunoassay (66). One complete acute 
obstruction model (complete unilateral ureteral obstruction (CUUO) for 48 hours) and one 
partial chronic obstruction model (partial unilateral ureteral obstruction (PUUO) for 10 weeks) 
was employed. In the CUUO model IL-1β, IL-6, TNF-α, and IL-10 showed significant 
differences in comparison with controls: IL-1β and IL-10 were detected at significantly 
decreased levels, with IL-6 and TNF-α found at significantly higher concentrations in urine 
from the left obstructed kidney. In the PUUO model only IL-6 showed a significant increase in 
urinary abundance. Another study compared the protein profiles in a PUUO model in 
neonatal rats (obstruction at 1 day of age, randomized into 4 groups: 1, 2 and 5 days of 
obstruction and sham surgery) using 2-D gel electrophoresis coupled to MS (2DE-MS) (67). 
Forty-three proteins with differential urinary abundance were identified, which were reported 
  
to be involved in the regulation of the cytoskeleton and actin, glucose metabolism, cell 
apoptosis, mitochondrial energy metabolism, oxidative stress, and endoplasmic reticulum 
stress. Electron transfer flavoprotein subunit beta (ETFB) identified as downregulated in 
urine by 2DE-MS was validated by immunoblot analysis. ETFB mRNA levels was also 
decreased in renal tissue from PUUO rats. 
Another 2DE-MS study using an adult CUUO (three time-points (12 h, 24 h and 72 h)) rat 
model was performed by Zhao et al. They identified 39 proteins with different urinary 
abundance between the sham operated group and the CUUO group (68). Cell apoptosis, 
energy metabolism, injuries of mitochondrion and oxidative stress were some of the 
biological processes associated with these proteins. In addition, based on immunoblot 
analysis and immunofluorescence staining and assessment of the mRNA levels in renal 
tissue, they confirmed changes of 3 proteins: peroxiredoxin-1 (PRDX-1) was increased, 
glutathione peroxidase 1 (GPX1) and glutathione S-transferase P1 (GSTP1) were 
decreased. This study allowed a better understanding between oxidative stress and 
obstructive nephropathy.  
To study the acute urinary proteomic alterations induced by bilateral ureteral obstruction 
(BUO), MS-based proteomics was applied in rats that were subjected for three different time-
points (2, 6, 24 h) to BUO (69). In this study 109 proteins associated with different biological 
processes involved in cytoskeleton and cytoskeletal regulation were identified. Western blots 
confirmed the selected results, demonstrating acute downregulation of proteins belonging to 
all three cytoskeletal components: the microfilament protein β-actin and the intermediate 
filament proteins pankeratin and vimentin, as well as β-tubulin, an important microtubular 
protein, were all downregulated. Furthermore, there was a significant upregulation of cofilin, 
an actin-binding protein. Table 2 summarizes potential urinary biomarkers of RTM identified 
in animal models.  
 
6. Expert commentary 
  
In recent years a substantial number of studies have performed urinary proteome analysis in 
order to identify potential biomarkers of RTM. Only a few urinary biomarkers have been 
found to be unequivocally associated to UPJO. This is the case for urinary TGF-β1 that in all 
studies increased in UPJO, and decreased after relief of the obstruction. Studies on urinary 
EGF, although initially promising, turned out to be less clear and with time it appeared that 
EGF can be a urinary marker for many diseases thereby losing its specificity for UPJO. This 
also points to the important fact that to be marked as a “biomarker” validation should be 
performed in independent studies.  
TGF-β1 and EGF were investigated as “isolated” markers of UPJO obstruction using ELISA 
and might perform better in a panel of markers. It has now been repeatedly observed that 
complex disease such as RTM cannot be faithfully described with single markers and panels 
of markers are more likely to “catch” the perturbed system, similarly to everyday medicine 
where a diagnosis is rarely based on a single observation. MS-based proteomics serves this 
goal. In this context it was observed, as described in detail above (sections 4.1-4.3), that 
panels of urinary peptides could predict the outcome in the different RTM, such as 51 UPJO-
specific biomarkers (51), 12 related to PUV (62) and 9 concerning VUR (38).  
 
7. Five-year view 
In the coming years these initial successes obtained with single or multiple biomarkers still 
need to be confirmed to be applicable in the clinic. This involves larger scale studies (several 
hundreds of individuals/trial) the reach sufficient power. This might involve, in addition to the 
peptide panels discovered with MS-based tools, combination of markers (e.g. ELISA panels 
including TGF-β1, EGF, cytokines observed in animal models, etc.).  
Finally, studies including other omics traits in urine (non-coding RNAs, metabolites, etc.) 
might allow adding additional markers to the panels and i) increase their specificity for the 
stratification of patients with RTM and ii) improve the understanding of the pathophysiology 
to allow optimised management of this frequent disease in children.   
 
  
8. Key issues 
• Urine is an important source of potential biomarkers, presenting several advantages 
such as the collection in large quantities, as a non-invasive method and as its stability.  
• Biomarker validation in an independent cohort is a crucial step for clinical proteomics, 
and it can be performed through mass spectrometry techniques (e.g. LC-MS, CE-MS) or 
immunoassay techniques (e.g. ELISA, WB). 
• RTM are congenital anomalies of the kidneys and urinary tract, and are more 
common in infants, but can be also presented in childhood and adulthood. 
• Development of non-invasive methods, such as urinary proteomics, can be useful to 
understand the progression of the different types of RTM, as well as to allow an early 
diagnosis, prognosis and a better clinical decision-making. 
• Several studies in clinical proteomics have been performed, and a panel of 
biomarkers is more efficient than the use of a single biomarker. 
Studies with high numbers of samples coupled to statistical analysis and an independent 
validation should be conducted to generate a classifier for RTM. 
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Figure 1: Different types of urinary tract malformations in humans.  
 
Normal System Ureteropelvic Junction Obstruction (UPJO)
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Figure 2: Example for an induced ureteral obstruction in rats. Reproduced with permission from the Danish Medical Journal. Madsen 
MG. Urinary biomarkers in hydronephrosis. Dan Med J 2013 Feb;60(2):B4582 (66). 
 
 
  
Table 1: Summary of potential urinary biomarkers for RTM in studies concerning human samples. 
Disease Biomarker Method Species Performance Pathways/ Biological Process Validity Reference 
UPJO 
TGF-β1 ELISA human Diagnosis 
Fetal development, 
cell differentiation 
(leading to renal 
fibrosis) 
significant 
(AUC=0.75) (36-39) 
EGF ELISA human Diagnosis Modulation of tubular cell growth 
questionable 
(AUC=0.79) 
(36;40-
43;52;54) 
MCP-1 ELISA human Diagnosis 
Specific chemotactic 
and activating factor 
for monocytes 
significant 
(AUC=0.78) (40;41;43) 
ATG ELISA human Diagnosis Growth factor activity significant (AUC=0.84) (44;45) 
KIM-1 ELISA human Diagnosis 
Kidney injury, 
tubulointerstitial 
inflammation and 
fibrosis 
significant 
(AUC=0.80) (46) 
NGAL ELISA human Diagnosis Activation of specific iron-dependent 
significant 
(AUC=0.92) (46;47) 
51 peptides 
(including 
different 
collagen 
fragments) 
CE-MS human Diagnosis and Prognosis Collagen turnover 
significant 
(AUC=0.92) (48;49;51) 
Different 
proteins LC-MS human Diagnosis 
Cell differentiation, 
signalling pathway questionable (53;54) 
  
Arginase 1 
(beside other 
proteins) 
LC-MS, 
WB, MRM human Diagnosis 
Urea Cycle 
(development of renal 
fibrosis) 
significant (52) 
GSTM1, 
HSPA1A 
(beside other 
74 proteins) 
LC-MS, WB human Diagnosis Stress response, transferase  significant (45) 
PUV 
12 peptides 
(including 
different 
collagen and 
GNAS 
fragments) 
CE-MS human Diagnosis and Prognosis 
Collagen turnover, 
Signal transduction 
significant 
(AUC=0.92) 
(58) 
AQP2, TGFβ, 
L1CAM 2D-MS, WB human Diagnosis 
Cell differentiation, 
transport 
significant 
(AUCTGFβ=0.79) 
(AUCL1CAM=0.80) 
(59) 
TGF-β1, TNF-
α ELISA human Diagnosis Cell differentiation significant (60) 
VUR 
9 peptides 
(including 
different 
collagen 
fragments, 
sodium/ 
potassium-
transporting 
ATPase 
fragment, 
CD99 antigen 
fragment) 
CE-MS human Diagnosis Collagen turnover significant (35) 
 
  
Table 2: Summary of potential urinary biomarkers for RTM identified on animal models. 
Disease Biomarker Method Species Performance Pathways/ Biological Process Validity Reference 
UPJO 
Arginase 1 
(beside other 
proteins) 
LC-MS, 
WB, MRM mice Diagnosis 
Urea Cycle 
(Development of renal 
fibrosis) 
significant (55) 
CUUO 
IL-1β, IL-6, 
TNF-α, IL-10 WB rat Diagnosis 
Cytokine activity, 
Signaling and 
regulatory/growth 
factors 
significant (66) 
PRDX1, 
GSTP1, GPX1 2D-MS, WB rat Diagnosis 
Antioxidation related 
to oxidative stress significant (68) 
PUUO 
IL-6 WB rat Diagnosis Cytokine activity, Growth Factor significant (66) 
ETFB 2D-MS, WB rat Diagnosis 
Specific electron 
acceptor (associated to 
fibrotic processes) 
significant (67) 
BUO 
β-actin, 
pankeratin, 
vimentin, β-
tubulin, cofilin 
LC-MS, 
ELISA rat Diagnosis 
Cytoskeletal 
regulation significant (69) 
 
 
 
 
 
